Headache and Migraine

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Over a 12-month treatment period, fremanezumab afforded significantly greater reductions in monthly migraine days and higher responder rates compared with placebo for patients with chronic migraine.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

A literature review of the evidence for erenumab (Aimovig; Amgen) treatment in migraine suggests that certain patients would benefit from initiating treatment at 140 mg rather than 70 mg and that the higher dose more effectively prevents progression to chronic disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 15, 2022.

The mean bodyweight-normalized infant rimegepant dose was 0.0005 mg/kg/day, and the mean estimated relative infant dose was 0.51%, therefore indicating the study drug results in less than 1% relative infant dose in human milk.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Among triptan non/past use and current use patients, investigators observed refill decreases of 15.3% and 16.8%, respectively, in the 9 months following rimegepant treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 8, 2022.

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

The assistant professor of neurology at the University of Pennsylvania discussed the similarities observed between the results of neurological exams in patients with COVID-19 vs other respiratory infections. [WATCH TIME: 3 minutes]

All patients received 100% of the intended stimulations, with no reported deaths, stimulation site reactions, or any cases of acute coronary syndrome or symptomatic intracerebral hemorrhage.

In the AAN 2022 presidential plenary session, a trio of neurologists discussed a variety of issues stemming from the COVID-19 pandemic and how they impacted research efforts in neurological diseases.

Here's what is coming soon to NeurologyLive®.

At 2 hours post-stimulation, 42.5% of those on the Cefaly device had absence of most bothersome symptoms compared with 34.1% of those in the sham group.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Through both 24 and 48 hours after single-dose treatment, 85% and 83% of patients, respectively, remained free of the need for rescue medication.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 1, 2022.

The investigators concluded that the MIDAS questionnaire may be a useful tool in the development, testing, and prescription of cost-effective medications for those with migraine whose direct and indirect costs are high.

Abnormal scores on cognitive testing persisted in 50% of patients without a pre-COVID history of cognitive abnormalities, irrespective of the presence or absence of a neurological complication during hospitalization.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.